中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
24期
1573-1576
,共4页
徐杰%齐大亮%李绪斌%王瑞霞
徐傑%齊大亮%李緒斌%王瑞霞
서걸%제대량%리서빈%왕서하
恶性胸腔积液%重组人血管内皮抑制素%奈达铂%非小细胞肺癌
噁性胸腔積液%重組人血管內皮抑製素%奈達鉑%非小細胞肺癌
악성흉강적액%중조인혈관내피억제소%내체박%비소세포폐암
malignant pleural effusion%recombinant human endostatin%nedaplatin%non-small cell lung cancer
目的：观察重组人血管内皮抑制素（恩度）联合化疗治疗非小细胞肺癌恶性胸腔积液的短期疗效及安全性。方法：70例恶性胸腔积液患者经皮穿刺置管彻底引流胸腔积液，随机分成两组，治疗组35例，重组人血管内皮抑制素60 mg 联合奈达铂60 mg胸腔内注入；对照组35例为单纯奈达铂60 mg胸腔内注入。将重组人血管内皮抑制素及奈达铂经胸腔置管于胸腔内注射，每周1次，连用2周。1个月复查，比较两组的总有效率及不良反应发生率。结果：治疗组总有效率为74.28%，高于对照组的48.57%（P<0.05）。两组均有恶心、呕吐、外周白细胞减少等不良反应，但差异均无统计学意义（P>0.05）。结论：胸腔内灌注奈达铂联合重组人血管内皮抑制素疗效优于单纯奈达铂，且不增加治疗的不良反应，重组人血管内皮抑制素联合化疗治疗恶性胸腔积液是一种安全有效的治疗方法。
目的：觀察重組人血管內皮抑製素（恩度）聯閤化療治療非小細胞肺癌噁性胸腔積液的短期療效及安全性。方法：70例噁性胸腔積液患者經皮穿刺置管徹底引流胸腔積液，隨機分成兩組，治療組35例，重組人血管內皮抑製素60 mg 聯閤奈達鉑60 mg胸腔內註入；對照組35例為單純奈達鉑60 mg胸腔內註入。將重組人血管內皮抑製素及奈達鉑經胸腔置管于胸腔內註射，每週1次，連用2週。1箇月複查，比較兩組的總有效率及不良反應髮生率。結果：治療組總有效率為74.28%，高于對照組的48.57%（P<0.05）。兩組均有噁心、嘔吐、外週白細胞減少等不良反應，但差異均無統計學意義（P>0.05）。結論：胸腔內灌註奈達鉑聯閤重組人血管內皮抑製素療效優于單純奈達鉑，且不增加治療的不良反應，重組人血管內皮抑製素聯閤化療治療噁性胸腔積液是一種安全有效的治療方法。
목적：관찰중조인혈관내피억제소（은도）연합화료치료비소세포폐암악성흉강적액적단기료효급안전성。방법：70례악성흉강적액환자경피천자치관철저인류흉강적액，수궤분성량조，치료조35례，중조인혈관내피억제소60 mg 연합내체박60 mg흉강내주입；대조조35례위단순내체박60 mg흉강내주입。장중조인혈관내피억제소급내체박경흉강치관우흉강내주사，매주1차，련용2주。1개월복사，비교량조적총유효솔급불량반응발생솔。결과：치료조총유효솔위74.28%，고우대조조적48.57%（P<0.05）。량조균유악심、구토、외주백세포감소등불량반응，단차이균무통계학의의（P>0.05）。결론：흉강내관주내체박연합중조인혈관내피억제소료효우우단순내체박，차불증가치료적불량반응，중조인혈관내피억제소연합화료치료악성흉강적액시일충안전유효적치료방법。
Objective: To study the efficacy and safety of the intrapleural injection of nedaplatin combined with recombinant hu-man endostatin (Endostar) in the treatment of malignant pleural effusion in non-small cell lung cancer (NSCLC) patients. Methods:Seventy patients diagnosed with NSCLC with malignant pleural effusion were treated by intrapleural injection. The subjects were divid-ed into two groups, as follows: 35 cases were injected with nedaplatin and Endostar (the treatment group) and 35 cases were injected with nedaplatin only (the control group). One month after the treatment, the clinical efficacy and toxicity were evaluated. The clinical ef-ficacy, quality of life, and toxic reaction were compared between the two groups. Results: The short-term clinical efficacy rate of the treatment group was 74.28%, whereas that of the control group was 48.57%, and the difference between the two groups was significant (P<0.05). Adverse effects such as nausea vomiting and leukopenia, occurred in both groups, but no significant differences were found between the two groups (P>0.05). Conclusion: The efficacy of the intrapleural injection of recombinant human endostatin combined with nedaplatin is superior to that of cisplatin alone in the treatment of malignant pleural effusion, without increasing chemotherapeutic toxicity.
